Since the release of our first recombinant cytochrome P450 (CYP) on 1st February 2000, we have rapidly expanded our portfolio to over 100 products covering human drug-metabolising enzymes (including 19 CYPs and 8 SULTs), murine and canine CYPs, 33 fine chemicals, and a range of antibodies. We have also obtained the prestigious ISO9001 quality accreditation.Drawing on our expertise in expressing recombinant cytochrome P450s and in drug metabolism, we also offer contract services both for custom protein expression and the production of drug metabolites.